About
Contact
Subscribe
e-Edition

Make Home Page

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Facebook
Twitter

- Site search

Home
News
Sports
- Local Sports
- National Sports
Business
Opinion
A & E
Life
Features & Magazines
- WOMEN
- 2026 Readers' Choice Awards
Classifieds
Weather
Obituaries
2026 Readers' Choice Winners

Recent Quotes

View Full List

My Watchlist

Create Watchlist

Indicators

Dow Jones Industrial Average

Markets:

Overview

News

Currencies

International

Treasuries

Arcturus Therapeutics Holdings Inc (NQ:ARCT)

8.935 -0.375 (-4.03%)

Delayed Quote Updated: 11:14 AM EST, Nov 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arcturus Therapeutics Holdings Inc

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Arcturus (ARCT) Q3 2026 Earnings Call Transcript ↗

November 06, 2026

Cash runway now reaches 2028 as cystic fibrosis enrollment nears completion.

Via The Motley Fool

Topics Earnings

What Arcturus Therapeutics (ARCT) Said on Its Q3 Earnings Call ↗

November 05, 2026

Arcturus Therapeutics (NASDAQ:ARCT) expects to complete enrollment in a mid-stage cystic fibrosis study by the end of 2026 and begin dosing a next-generation treatment for a rare liver disorder in the...

Via MarketBeat

Topics Earnings

Arcturus Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline Progress

November 05, 2026

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026

October 26, 2026

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics Holdings (NASDAQ:ARCT) Q1 2026 Results: Revenue Miss Weighs on Sentiment as Pipeline Advances ↗

May 07, 2026

Via Chartmill

Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform ↗

September 24, 2026

Arcturus Therapeutics (NASDAQ:ARCT) presented preliminary Phase II data for ARCT-810, its mRNA therapeutic candidate for ornithine transcarbamylase, or OTC, deficiency, while outlining plans to...

Via MarketBeat

Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform

September 23, 2026

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform

September 18, 2026

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics to Participate in Upcoming Investor Conferences

August 31, 2026

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

August 19, 2026

Via Chartmill

Stay updated with the stocks that are on the move in today's pre-market session. ↗

August 19, 2026

Via Chartmill

Arcturus (ARCT) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

Regaining vaccine rights and advancing rare disease programs toward key 2026 milestones.

Via The Motley Fool

Topics Earnings

Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline ↗

August 11, 2026

Arcturus Therapeutics (NASDAQ:ARCT) is positioning its mRNA platform around two rare-disease programs targeting cystic fibrosis and ornithine transcarbamylase deficiency, while its vaccine business is...

Via MarketBeat

Arcturus Therapeutics Q2 Earnings Call Highlights ↗

August 06, 2026

Arcturus Therapeutics (NASDAQ:ARCT) reported progress across its rare-disease pipeline during the second quarter of 2026, completed enrollment and dosing in its Phase II ornithine transcarbamylase...

Via MarketBeat

Topics Earnings

Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress

August 06, 2026

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026

July 28, 2026

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

July 20, 2026

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Thursday's session: gap up and gap down stocks ↗

July 02, 2026

Via Chartmill

Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis

July 02, 2026

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies ↗

June 05, 2026

Arcturus Therapeutics (NASDAQ:ARCT) President and CEO Joseph Payne outlined the company’s messenger RNA programs, vaccine approvals and upcoming clinical milestones during a presentation at the...

Via MarketBeat

Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

May 26, 2026

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus (ARCT) Q1 2026 Earnings Call Transcript ↗

May 08, 2026

Arcturus (ARCT) Q1 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Get insights into the top gainers and losers of Thursday's after-hours session. ↗

May 07, 2026

Via Chartmill

Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress

May 07, 2026

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026

April 27, 2026

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial Highlighting Biotech’s Shift Toward Science-Driven Asset Valuation

April 20, 2026

Via Investor Brand Network

Topics Artificial Intelligence

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

April 20, 2026

Via Investor Brand Network

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

April 20, 2026

From BioMedWire

Via GlobeNewswire

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

March 25, 2026

The widely followed investor has been buying stocks trading well below their all-time highs.

Via The Motley Fool

These Are the Only 3 Stocks That Cathie Wood Bought Last Week ↗

March 23, 2026

The growing investing icon was skimpy on her purchases last week, making the names she did buy that much more interesting.

Via The Motley Fool

Topics Artificial Intelligence ETFs

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

News
Sports
Opinion
Photo Galleries
Videos
Local Events
Classifieds
Obituaries

Services

About
Contact
Personnel
Advertise
Subscription Services
Promote Your Event
Dealer Locations
Email Alerts
Submission Forms

Contact Information

chroniclejournal.com
75 S. Cumberland Street
Thunder Bay, ON P7B 1A3
Phone: 807 343 6200
Email: circulation@chroniclejournal.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Arcturus Therapeutics Holdings Inc (NQ:ARCT)

All News about Arcturus Therapeutics Holdings Inc

Sections

Services

Contact Information

Follow Us